Skip to main content

Table 1 In vivo cardiac function in mice with experimental diabetic cardiomyopathy treated with vehicle control or AT-001

From: Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation

Parameter

Type 2 diabetes + VC

Type 2 diabetes + AT

Body weight (g)

41.8 ± 3

44 ± 2.4

Heart rate

441 ± 15

445 ± 13

LVID (mm), s

2.9 ± 0.1

2.8 ± 0.1

LVID (mm), d

4.3 ± 0.05

4 ± 0.1

Volume (μL); s

34.1 ± 2

30.9 ± 2.8

Volume (μL); d

83 ± 2.3

77 ± 6.1

Stroke volume (μL)

49.1 ± 2.5

46 ± 4.3

EF (%)

60 ± 2.6

59.6 ± 2.1

FS (%)

31.8 ± 1.8

31.5 ± 1.5

CO (ml • min−1)

21.4 ± 1.2

20.4 ± 2

LVAWT (mm); s

1.1 ± 0.04

1.1 ± 0.06

LVAWT (mm); d

0.7 ± 0.04

0.67 ± 0.02

LVPWT (mm); s

1.32 ± 0.04

1.33 ± 0.04

LVPWT (mm); d

0.99 ± 0.02

0.97 ± 0.03

LV mass Cor (mg)

116 ± 6.2

99 ± 4.5

e’/a’

1.28 ± 0.05

1.52 ± 0.07a

E/e’

34.1 ± 1.3

28.7 ± 1.1a

E/A

1.4 ± 0.04

1.7 ± 0.1a

  1. Values represent mean ± SEM
  2. VC vehicle control, AT AT-001, CO cardiac output, Cor corrected, d diastole, s systole, EF ejection fraction, FS fractional shortening, LV left ventricular, LVID LV internal diameter, LVAWT LV anterior wall thickness, LVPWT LV posterior wall thickness
  3. aP < 0.05 significantly different from vehicle control-treated mice
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840